Cryptate compounds and methods for diagnosis and therapy

Details Cryptate compounds and methods for diagnosis and therapy Cryptate compounds and methods for diagnosis and therapy

2005-03-22

2005-03-22

Hartley, Michael G. (Department: 1616)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

In an organic compound

C424S009363, C424S001690, C424S001770, C540S465000, C540S467000, C540S469000, C540S456000

Reexamination Certificate

active

06869589

ABSTRACT:
The present invention relates to cryptate compounds useful as chelating agents. In particular, the present invention relates to functionalized derivatives of certain cryptate compounds. These functionalized derivatives are suitable for use in radiolabelling and similar applications. The present invention also relates to a method for diagnosis or therapy of a disease utilizing functionalized derivatives of cryptase compounds. In one embodiment, the present invention relates to a compound which is capable of being radiolabelled of general formula (I) in which n represents an integer from 2 to 4, where each R4and R5is independently selected from —H, CH3, COOH, NO2, CH2OH, H2PO4, HSO3, CN, C═ONH2and CHO; X and Y are the same or different and are selected from the group of C—R, N, P and C—Z in which R represents a hydrogen or halogen atom or a hydroxyl, nitro, nitroso, amino, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or cyano group, or a group of the formula —COOR′, COCOOR′, NH—COCH2Br, —NH—CO—CH═CH—COOR′ in which R′ is a hydrogen atom or alkyl group; or, W is selected from the group of NH, S and O; and Z is a functionalized linkage group which is capable of binding said compound of formula (I) to a molecular recognition unit and wherein at least one of X and Y is C—Z; or a pharmaceutically acceptable salt thereof

REFERENCES:
patent: 4741900 (1988-05-01), Alvarez et al.
patent: WO 9531202 (1995-11-01), None
Behm C A et al.: Novel Cationic Surfactants Derived from Metal Ion Cage Complexes: Potential Antiparasitic Agents, Australian Journal of Chemistry, vol. 48, No. 5, 1995, pp. 1009-1030, XP000573096.
Yeh et al.: Synthesis and Characterization of Cobalt-Cage Complexes with Pendant Phenol Groups Inorg. Chem., vol. 35, 1996, pp. 3828-3835, XP002191507.
Lawrence et al.: Organic Substituent Effects in Macrobicyclic (Hexaamine) cobalt (III/II) Complexes: A New Method of Obtaining Polar Substituent Constants, INORG. Chem., vol. 29, 1990, pp. 4808-4816, XP001056887.
SKOV: Effect of Protonation on the Electronic Spectra of Some Cobalt (III) Cage Complexes, ACTA Chem. SCAND., vol. 46, No. 5 1992, pp. 492-493, XP001056917.
Achilleos et al.: Synthesis and Characterization of Pendant Arm Encapsulated Complexes of Cobalt (III), Aust. J. Chem. vol. 42, No. 5, 1989, pp. 649-657, XP001056874.
Gerald A. Bottomley, et al., “The Synthesis and Structure of Encapsulating Ligands: Properties of Bicyclic Hexamines”, Aust. J. Chem., 1994, vol. 47, pp. 143-179.

Affiliated with

Also associated with

Rating

Cryptate compounds and methods for diagnosis and therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cryptate compounds and methods for diagnosis and therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cryptate compounds and methods for diagnosis and therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3420271